All In Biotech

Drug Trial Radar · NCT02843581

Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer

Last checked: Nov 19, 2026Latest source record: Sep 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Jul 1, 2016

Primary completion

Jul 1, 2017

Study completion Jul 1, 2019

Sponsor

Lead sponsor
Fuda Cancer Hospital, GuangzhouAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shenzhen Hank Bioengineering Institute
First posted
Jul 26, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced esophageal cancer.

Conditions

  • Metastatic Esophageal Cancer

Interventions

  • CryosurgeryDevice

    Argon-helium cryosurgical system

  • NK immunotherapyBiological

    Nutral killer cell immunotherapy for more than 6 times

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relief degreeTime frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fuda cancer institute in Fuda cancer hospital

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.